In fact, a recent study by Ma et al. showed that an EBV(+) NPC patient with aggressive recurrence had a complete response to a PD-L1 inhibitor, Nivolumab [96], highlighting the potential impact of an active immune recognition in NPC treatment response and outcome. This evidence concerns the gene CD274 and nasopharyngeal carcinoma.